

IND SAFETY REPORT: INITIAL WRITTEN REPORT

TO: Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA

FAX: 301-796-9845

1. IND NUMBER 109493 63383	2. AGENT NAME MK-2206 OSI-774 (erlotinib, Tarceva®)	3. DATE July 6, 2011
--	---	--------------------------------

4. SPONSOR
Division of Cancer Treatment and Diagnosis, National Cancer Institute

5. REPORTER'S NAME, TITLE, AND INSTITUTION L. Austin Doyle, MD-Senior Investigator for Investigational Therapeutics 2, Investigational Drug Branch, CTEP, DCTD, NCI Helen Chen, MD-Associate Branch Chief for Investigational Therapeutics 3, Investigational Drug Branch, CTEP, DCTD, NCI	6. PHONE NUMBER 301-496-1196 7. FAX NUMBER 301-402-0428
--	--

8a. PROTOCOL NUMBER (AE #) 8698 (AE#1964323)	8b. AE GRADE: AE Grade 3: Urinary tract infection
--	---

9. PATIENT IDENTIFICATION COH-009	10. AGE 50 yrs	11. SEX Female
---	--------------------------	--------------------------

12. DESCRIPTION OF ADVERSE EVENT
The patient is a 50-year-old female with non-small cell lung cancer who experienced grade 3 urinary tract infection while on a phase 2 trial using the investigational agents MK-2206 and erlotinib. She began her first course of treatment on April 8, 2011, and received the last doses of MK-2206 and erlotinib on May 14, 2011 (Cycle 2, Day 9). On May 7, 2011 (Cycle 2, Day 2), the patient presented to the emergency room with grade 2 fever and complaints of excessive aphasia. She was admitted to the hospital for further evaluation. A CT scan of the chest ruled out pneumonia, and a urinalysis indicated that the patient had a urinary tract infection. She was hydrated and started on Levaquin®. A CT scan of the brain indicated that there were no new brain metastases. She was discharged on May 8, 2011. On May 14, 2011, the treating physician decided to hold the investigational agents for one week. Additional information has been requested from the investigational site. There is a reasonable possibility that the experience may have been caused by the drugs.

13. DOSE, ROUTE, AND SCHEDULE
Cycle: 28 Days
MK-2206: 45 mg PO every other day and Erlotinib: 150 mg PO daily

14. DATES OF TREATMENT
The patient started the investigational therapy on April 8, 2011, and received the last doses of MK-2206 and erlotinib on May 14, 2011 (Cycle 2, Day 9).

15. ACCRUAL AND IND EXPERIENCE
Number of patients enrolled in NCI-sponsored clinical trials using MK-2206 = 70 and erlotinib = 3,537. There have been no other cases of urinary tract infection reported to the NCI through AdEERS as serious adverse events for MK-2206. There have been 9 other cases of urinary tract infection reported to the NCI through AdEERS as serious adverse events for erlotinib.

16. COMMENTS
AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d) (2).
DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.